Caladrius Biosciences, Inc. (NASDAQ:CLBS) Releases Earnings Results, Beats Expectations By $0.08 EPS
Caladrius Biosciences, Inc. (NASDAQ:CLBS) announced its earnings results on Thursday. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.08, Morningstar.com reports. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 742.11%.
Shares of Caladrius Biosciences (NASDAQ CLBS) opened at 4.00 on Friday. Caladrius Biosciences has a 52 week low of $2.65 and a 52 week high of $7.79. The stock’s 50 day moving average is $4.19 and its 200-day moving average is $4.66.
Several hedge funds and other institutional investors have recently bought and sold shares of CLBS. Vanguard Group Inc. boosted its position in Caladrius Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares during the last quarter. Renaissance Technologies LLC boosted its position in Caladrius Biosciences by 34.3% in the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares during the last quarter. Finally, KCG Holdings Inc. boosted its position in Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares during the last quarter. Hedge funds and other institutional investors own 6.64% of the company’s stock.
A number of brokerages have recently weighed in on CLBS. HC Wainwright set a $7.00 target price on shares of Caladrius Biosciences and gave the company a “buy” rating in a research note on Friday, May 19th. Zacks Investment Research raised shares of Caladrius Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. Finally, ValuEngine raised shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 10th.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/12/caladrius-biosciences-inc-nasdaqclbs-releases-earnings-results-beats-expectations-by-0-08-eps.html.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.